Confo Therapeutics
Belgium - GhentDiagnostics
Focus: Confo Therapeutics is a Belgium-based biotech company founded in 2018 specializing in GPCR-targeted therapeutics for metabolic diseases. The company is in early-stage development with one Phase 1 program.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES B
Open Jobs
1
Should You Work at Confo Therapeutics?
AI assessmentBest suited for early-stage biotech explorers willing to take clinical and financial risk for potential upside in GPCR therapeutics; not recommended for those seeking near-term job security or clinical milestone visibility.
Why Work Here
- Early-stage opportunity in validated GPCR biology targeting metabolic disease, a large unmet-need market with multiple competitors pursuing similar targets.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
CFTX-1554
HealthyClinical Trials (1)
NCT05260658Safety and Tolerability of CFTX-1554 in Healthy Subjects
Phase 1Help build intelligence for Confo Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.